FDA and CMS Address Regulatory Challenges for AI in Clinical Settings
The U.S. Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) are reportedly working to develop a clear regulatory pathway for artificial intelligence in healthcare. This effort aims to prevent a "regulatory logjam" as more states and healthcare providers explore integrating AI into clinical settings. The agencies are focused on establishing oversight for generative AI devices and their potential impact on providers.
3 articles from 3 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
3 outlets covered “FDA and CMS Address Regulatory Challenges for AI in Clinical Settings”. All of them report the following:
- FDA and CMS are involved in regulatory efforts
- The focus is on AI in clinical settings/medical AI
- The goal is to avoid regulatory logjam or gridlock
- More states and providers are looking to test/use AI
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.